|
CDER Advisory Committee Staff
Updated August 2008
|
Director:
Igor Cerny, Pharm.D.
HFD-21, (301) 827-7001Deputy Director:
Jayne Peterson, R.Ph., J.D.
HFD-21, (301) 827-7001
Team Leaders:
LT Cicely Reese, Pharm.D.
HFD-21, (301) 827-7001
Karen Templeton-Somers, Ph.D.
HFD-21, (301) 827-7001
Lead Public Health Analyst:
Susan Peters
HFD-21, (301) 827-7002
Cynthia Abernethy
HFD-21, (301) 827-7001
Public Health Analysts:
LT Katherine Kim, Pharm.D. (301) 827-7001
Kimberly Kline (301) 827-7001
Cathy Miller (301) 827-7001
CDR Karen Bryant, R.N. (301) 827-7001
Ji LaRose, Pharm.D. (301) 827-7001
Ahn Vu (301) 827-7001
|
Project Specialists:
Mary Barnes (301) 827-7002
John Lautmann (301) 827-7002
Charlene Burroughs (301) 827-7001
Vontina Collick (301) 827-7002
Laurie Davie (301) 827-7002
Health Science Administrator/Data Base Administrator:
LCDR Sohail Mosaddegh, Pharm.D. (301) 827-7001
Technical Information Specialist:
LCDR Thiep Vo (301) 827-7001
Office Manager:
Chris Shipe (301) 827-7001 ACS Writer Editor:
Robin Spencer (301) 827-7001 |
|
Anesthetic and Life Support Drugs Advisory Committee
Kalyani Bhatt, B.Sc., M.D.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Anesthesia, Analgesia, and Rheumatology Products
ODE II |
|
Anti-Infective Drugs Advisory Committee
Janie Kim, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Anti-Infective and Ophthalmologic Products
ODE IV |
|
Antiviral Drugs Advisory Committee
Paul Tran, R.Ph.
Designated Federal Official
HFD-21 (301) 827-7001
Division of Antiviral Products
ODE IV |
|
Arthritis Advisory Committee
LT Nicole Vesley, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Anesthesia, Analgesia, and Rheumatology Products
ODE II |
|
Cardiovascular and Renal Drugs Advisory Committee
Elaine Ferguson, R.Ph., M.S.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Cardiovascular and Renal Products
ODE I |
|
Dermatologic and Ophthalmic Drugs Advisory Committee
LT Yvette Waples, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Dermatology and Dental Products
ODE III |
|
Drug
Safety and Risk Management Advisory Committee
Elaine Ferguson, R.Ph., M.S.
Designated Federal Official
HFD-21, (301) 827-7001
Office of Surveillance and Epidemiology |
|
Endocrinologic and Metabolic Drugs Advisory Committee
Paul Tran, R.Ph.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Metabolism and Endocrinology Products
ODE II |
|
Gastrointestinal Drugs Advisory Committee
Kristine Khuc, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Gastroenterology Products
ODE III |
|
Nonprescription Drugs Advisory Committee
LCDR Diem-Kieu Ngo, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Office of Nonprescription Products |
|
Oncologic Drugs Advisory Committee
LT Nicole Vesley, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Office of Oncology Drug Products |
|
Peripheral and Central Nervous System Drugs Advisory Committee
LCDR Diem-Kieu Ngo, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Neurology Products
ODE I |
|
Pharmaceutical Science, Advisory Committee
LCDR Sohail Mosaddegh, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Office of Pharmaceutical Science |
|
|
Psychopharmacologic Drugs Advisory Committee
LT Yvette Waples, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Psychiatry Products
ODE I |
|
Pulmonary-Allergy Drugs Advisory Committee
Kristine Khuc, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Pulmonary and Allergy Products
ODE II |
|
Reproductive Health Drugs,
Advisory Committee
Kalyani Bhatt, B.Sc., M.S.
Designated Federal Official
HFD-21, (301) 827-7001
Division of Reproductive and Urologic Products
ODE III |
|
Back to Top Back to
Human Drug Advisory Committee Information
Last Updated: August 8, 2008 |
|